Resmed (RMD) Accumulated Expenses (2010 - 2026)

Resmed has reported Accumulated Expenses for 17 years, with the latest figure at $446.1 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 15.49% year-over-year to $446.1 million; the trailing twelve-month figure through Mar 2026 stood at $446.1 million (up 15.49% YoY), and the FY2025 full-year result was $402.3 million, up 6.51% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $446.1 million, up from $391.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $446.1 million in Q1 2026, with the low at $312.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $363.2 million across 5 years, with a median of $356.1 million in 2024.
• Annual changes were most pronounced in 2022 — Accumulated Expenses advanced 18.22% — and 2024, when it increased 2.51%.
• Resmed's Accumulated Expenses stood at $312.2 million in 2022, then rose by 6.4% to $332.1 million in 2023, then climbed by 6.14% to $352.5 million in 2024, then rose by 11.05% to $391.5 million in 2025, then advanced by 13.96% to $446.1 million in 2026.
• The last three Accumulated Expenses figures came in at $446.1 million (Q1 2026), $391.5 million (Q4 2025), and $395.8 million (Q3 2025), per Business Quant data.